Global Biosimilars Market Share Grows at a Staggering CAGR of 13.43%

Introduction

Straits Research released its highly anticipated report, “Global Biosimilars Market Size & Outlook, 2026-2034”. According to the study, the global market size is valued at USD 37.73 billion in 2025 and is projected to expand to USD 116.90 billion by 2034, registering a compound annual growth rate (CAGR) of 13.43%.

Market Dynamics

The market growth is attributed to the government-led cost containment and access strategies. Proactive government policies, such as the National Volume-Based Procurement policy for insulin in China, strategically link the purchasing volumes to competitive pricing, differentiate price cuts between the brand-name and biosimilar products, which further boosts the domestic manufacturing capacity, and create a suitable framework for affordable diabetes management. Similarly, in Singapore, value-driven healthcare initiatives in public institutions have fuelled high adoption rates of biosimilars through reduced treatment costs, generating significant system-wide savings. Moreover, collaborative initiatives at the international level present a significant market opportunity as it enhance the growth of the biosimilar sector via early and easy availability of the products in the market. For example, the Biosimilar Work Sharing Initiative (BSWSI) is an initiative from the Access Consortium for the assessment of biosimilar applications. This access consortium includes countries such as Canada, the UK, Australia, Switzerland, and Singapore. Such an initiative creates market opportunity by enabling companies to secure approvals in multiple countries through a single application, which further facilitates faster access of biosimilars to patients by avoiding repetitive review processes.

Market Highlights

• Drug class: According to Straits Research, the monoclonal antibodies segment dominated the market in 2025, with a revenue share of 43.78%.
• Indication: By indication, the Oncology segment held the highest revenue share of 34.3% in 2025.
• Distribution channel: The hospital pharmacies dominate the market, fuelled by their ability to administer biosimilars under medical supervision and to maintain stringent storage and cold chain requirements necessary to preserve the stability and effectiveness of these products.
• Regional Insights: Europe dominates with over 38.13% share, driven bythe strong presence of pharmaceutical companies in the region, all of which are accelerating biosimilar adoption.

Competitive Players

1. Biocon
2. CELLTRION INC.
3. Teva Pharmaceutical Industries Ltd.
4. Samsung Bioepis
5. Organon
6. Pfizer Inc.
7. Amgen Inc.
8. Accord BioPharma, Inc.
9. Shanghai Henlius Biotech, Inc.
10. Amneal Pharmaceuticals LLC.
11. Sandoz Group AG
12. Bio-Thera Solutions, Ltd.
13. Meitheal Pharmaceuticals
14. Boehringer Ingelheim
15. Fresenius Kabi AG
16. Formycon AG
17. Tanvex BioPharma Inc.
18. Alvotech
19. Biogen
20. Reddy’s Laboratories Ltd.
21. Others

Recent Developments

Segmentation

1. By Drug Class (2026-2034)
   1. Monoclonal Antibodies
   2. Granulocyte Colony-Stimulating Factors
   3. Erythropoiesis-Stimulating Agents
   4. Insulin Analogs
   5. Others
2. By Indication (2026-2034)
   1. Oncology
   2. Autoimmune & Inflammatory Diseases
   3. Diabetes
   4. Blood Disorders
   5. Ophthalmology
   6. Others
3. By Distribution Channel (2026-2034)
   1. Hospital Pharmacies
   2. Drug Stores and Retail Pharmacies
   3. Online Pharmacies